Oura Files IPO S-1: $1.21 Billion Revenue, 74% Growth Confirmed

Oura just made its finances public. The S-1 filed with the SEC confirms $1.21 billion in nine-month revenue, a 74% year-over-year increase, and a Nasdaq ticker of OURA. The $924 million net loss sounds alarming until you read the footnotes: it is entirely an accounting artifact from preferred-stock conversion, not operational bleeding. This is a company selling a lot of rings.

What the S-1 Actually Tells Athletes

Oura's core product is a PPG-based optical sensor ring that tracks heart rate variability, skin temperature, respiratory rate, and SpO2 throughout the night. No GPS. No barometric altimeter. No chest strap ECG. What it does, it does in a small form factor that Garmin, Whoop, and Polar cannot match for sleep comfort. The ring sits on your finger, where blood vessels are closer to the surface than at the wrist, which gives the optical sensor a cleaner signal than a Garmin Fenix 8 or an Apple Watch Ultra 2 worn loosely at night. That is the hardware pitch, and $1.21 billion in nine months says a lot of people are buying it.

Four new board members were added the day before the S-1 filing. That is standard pre-IPO governance housekeeping, but it does mean Oura is now a very different company than the Finnish startup that launched Gen 1 in 2015. Dexcom CEO Kevin Sayer was among those named, which signals a clear push toward continuous health monitoring beyond fitness. The company is not positioning itself against Garmin or Coros. It is positioning itself against clinical-grade wearables and insurance-linked health programs.

How Oura Compares to Whoop, Garmin, and Polar

For endurance athletes, the honest comparison is Oura versus Whoop 5.0. Both are screenless, subscription-optional recovery trackers. Whoop charges $30 per month after hardware; Oura charges $5.99 per month after the $349 ring purchase. Whoop uses a wrist-worn optical PPG sensor and leans hard on strain scores and HRV-based recovery coaching. Oura leans on sleep staging and readiness scores derived from the same HRV and temperature data. Neither gives you real-time pace, power, or GPS track. If you are a triathlete or runner who needs split data mid-workout, you still need a Garmin Forerunner 965, a Coros Pace 3, or a Polar Vantage V3 on your wrist. Oura is a companion device, not a primary sports watch.

Whoop has faced its own market turbulence. Polar is currently dealing with a trade dress lawsuit from Whoop, which you can read about in [Polar's public denial of those claims](/en/articles/polar-denies-whoop-trade-dress-infringement-claims-publicly-2026-05-16). Meanwhile Garmin's own financials show Fenix revenue softening even as the brand pushes into new sensor categories like muscle oxygen (SmO2), covered in detail [here](/en/articles/garmin-targets-strava-fenix-revenue-slips-smo2-goes-mainstream-2026-05-16). The recovery tracker market is genuinely crowded right now, and Oura's IPO is a direct bet that sleep and readiness data have more long-term consumer value than GPS lap splits.

Real Use Cases for Endurance Athletes

Where Oura earns its place in a training stack is recovery monitoring across a hard training block. A Hyrox athlete doing three heavy sessions per week gets meaningful data from nightly HRV trends and the readiness score. A cyclist riding 15-plus hours per week can use Oura's temperature deviation alerts as an early warning for overreaching or illness, sometimes 24 to 48 hours before subjective fatigue hits. CrossFitters report similar early-warning value. Swimmers find it genuinely useful because it survives pool sessions (water resistance rated to 100 meters) and does not interfere with goggle straps or kickboard drills the way a bulky GPS watch does.

The limitation for serious runners and triathletes is real, though. No GPS means no pace data. No barometric altimeter means no elevation gain. No optical heart rate during swimming means no pool stroke count or SWOLF. You are paying $349 plus subscription for recovery intelligence, full stop. Garmin's cheaper devices like the Forerunner 165 at around $249 give you GPS, optical wrist PPG, sleep tracking, and HRV status without a subscription. Coros Pace 3 at $229 goes further with a longer battery. For athletes who are already subscription-fatigued, that math is uncomfortable.

What is missing from the Oura picture is transparent algorithm disclosure. The readiness score and sleep stage classifications are proprietary black boxes. Polar's Nightly Recharge and Garmin's Body Battery are also opaque, but Polar at least publishes research partnerships with universities. Oura has published some validation studies, but the S-1 does not commit to any accuracy benchmarks for its SpO2 or HRV readings versus clinical references. For an athlete making training decisions on this data, that matters.

Oura going public is worth watching even if you never buy the ring. An IPO brings regulatory disclosure requirements and third-party audits that will force more transparency about sensor accuracy claims across the whole wearable industry. Strava is also reportedly eyeing a public listing, which you can read about [here](/en/articles/strava-ceo-confirms-ipo-plans-after-garmin-partnership-dispute-2026-05-16). The wearable data ecosystem is consolidating fast, and Oura's $1.21 billion revenue run rate puts it squarely in the conversation with the biggest names in the sport.

Buy the Oura Ring 4 if you want the best passive sleep and recovery tracking available in a ring form factor and you already own a capable GPS watch. Skip it if you are looking for a single-device solution or if subscription costs add up painfully against your training budget. The direct competitor is Whoop 5.0 on recovery focus, but Oura wins on form factor and lower long-term subscription cost. At $349 plus $5.99 per month, it is a premium companion. The IPO does not change what the ring does. It just means the company will be around long enough to keep updating the firmware.